Ultralife (ULBI) Q1 2026 Earnings Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: NASDAQ.COM
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ULBI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ULBI
About ULBI
Ultralife Corporation offers products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government, defense and commercial sectors. Its segments include Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design. Its brands include Ultralife, Ultralife HiRate, Lithium Power, McDowell Research, AMTI, ABLE, ACCUTRONICS, ACCUPRO, ENTELLION, SWE Southwest Electronic Energy Group, SWE SEASAFE, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultralife (ULBI) Q1 2026 Earnings Transcript
See More
Ultralife Corporation Q1 2026 Earnings Call Insights
- Financial Performance Overview: Ultralife reported Q1 revenue of $47.4 million, down from $50.7 million in Q1 2025, with an operating loss of $0.2 million leading to a loss of $0.03 per share, primarily due to shipment delays and plant reorganizations impacting profitability.
- Record Backlog Achievement: The company exited the quarter with a record backlog of $115.1 million, including over $12 million from new products released in the past year, indicating strong future growth potential despite current operational challenges.
- Operational Efficiency Improvement Plans: Management has implemented measures to enhance production efficiency, including new plant leadership and training for direct labor resources, with corrective actions expected to start eliminating major scrap sources by mid-year, aimed at improving overall gross margins.
- Communication Systems Business Outlook: Despite underwhelming performance in Q1, management emphasized the launch of multiple new products to stabilize revenue, with plans to rebuild the revenue base of the Communication Systems segment in 2026, reflecting confidence in future growth.
See More
Ultralife Reports Q1 Earnings with Losses
- Earnings Overview: Ultralife reported a Q1 GAAP EPS of -$0.03 with revenues of $47.4 million, reflecting a 6.5% year-over-year decline, indicating increased competitive pressure in the market.
- Gross Margin Decline: The gross profit stood at $10.1 million, or 21.3% of revenue, down from $12.7 million and 25.1% last year, highlighting the negative impact of rising costs on profitability.
- Operating Loss: The company recorded an operating loss of $0.2 million, including one-time costs of $1.7 million, compared to a profit of $3.4 million in the same quarter last year, signaling intensified financial challenges.
- Market Reaction: Given the poor financial performance, Ultralife's stock price may face pressure, prompting investors to monitor the company's future strategic adjustments and cost control measures to enhance profitability.
See More
Ultralife Corporation to Report Q1 2026 Results
- Earnings Release Schedule: Ultralife Corporation is set to report its first quarter financial results for the period ending March 31, 2026, before the market opens on May 8, 2026, which is expected to provide investors with the latest performance data to assess the company's financial health.
- Investor Conference Call: The management will host an investor conference call and simultaneous webcast at 8:30 AM ET on the same day, aiming to communicate directly with investors, enhance transparency, and boost investor confidence.
- Pre-registration Requirement: To ensure a smooth connection to the conference call, participants are required to pre-register using the provided link, a measure designed to streamline the participation process and reduce interaction with operators, thereby improving meeting efficiency.
- Live Webcast and Replay: The call will be available via live webcast in the Events & Presentations section of the company's website, and investors who cannot listen live will have access to a replay shortly after the call, ensuring widespread dissemination and access to information.
See More
Ultralife Reports Q4 Revenue Growth Amid Losses
- Revenue Growth: Ultralife reported Q4 revenue of $48.5 million, a 10.6% year-over-year increase, with full-year revenue reaching $191.2 million, reflecting a 16.2% growth, indicating strong performance in the battery and energy products segment.
- Loss Situation: Despite revenue growth, Ultralife reported an operating loss of $10.6 million for Q4 and a full-year loss of $5.9 million, resulting in a loss of $0.35 per share, highlighting the negative impact of non-cash impairments on financials.
- Backlog Growth: The company’s backlog reached $110.2 million at the end of Q4, a 22.1% increase from the previous quarter, indicating strong future demand, particularly in the medical and industrial sectors.
- Communication System Challenges: The communication systems segment experienced a 35.2% revenue decline, primarily due to delayed orders from the US government shutdown, revealing profitability pressures faced by this segment in the short term.
See More
Ultralife Reports Q4 Results with Revenue Growth and Improved EBITDA
- Financial Performance: Ultralife's Q4 report reveals a GAAP EPS of -$0.45, indicating a loss; however, revenue reached $48.48 million, reflecting a 10.6% year-over-year increase, showcasing the company's sales growth potential in the market.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose to $5.7 million, up from $3.9 million in the same quarter last year, indicating enhanced operational efficiency and effective cost management.
- Increased Backlog: Ultralife's backlog stood at $110.2 million at the end of 2025, compared to $90.3 million at the end of Q3, demonstrating strong future revenue support and sustained market demand.
- Optimistic Market Outlook: Despite reporting a loss, Ultralife's revenue and EBITDA growth, along with the increase in backlog, suggest a solid development potential for the company in future market competition.
See More
Ultralife (ULBI) Q1 2026 Earnings Transcript
See More
Ultralife Corporation Q1 2026 Earnings Call Insights
- Financial Performance Overview: Ultralife reported Q1 revenue of $47.4 million, down from $50.7 million in Q1 2025, with an operating loss of $0.2 million leading to a loss of $0.03 per share, primarily due to shipment delays and plant reorganizations impacting profitability.
- Record Backlog Achievement: The company exited the quarter with a record backlog of $115.1 million, including over $12 million from new products released in the past year, indicating strong future growth potential despite current operational challenges.
- Operational Efficiency Improvement Plans: Management has implemented measures to enhance production efficiency, including new plant leadership and training for direct labor resources, with corrective actions expected to start eliminating major scrap sources by mid-year, aimed at improving overall gross margins.
- Communication Systems Business Outlook: Despite underwhelming performance in Q1, management emphasized the launch of multiple new products to stabilize revenue, with plans to rebuild the revenue base of the Communication Systems segment in 2026, reflecting confidence in future growth.
See More
Ultralife Reports Q1 Earnings with Losses
- Earnings Overview: Ultralife reported a Q1 GAAP EPS of -$0.03 with revenues of $47.4 million, reflecting a 6.5% year-over-year decline, indicating increased competitive pressure in the market.
- Gross Margin Decline: The gross profit stood at $10.1 million, or 21.3% of revenue, down from $12.7 million and 25.1% last year, highlighting the negative impact of rising costs on profitability.
- Operating Loss: The company recorded an operating loss of $0.2 million, including one-time costs of $1.7 million, compared to a profit of $3.4 million in the same quarter last year, signaling intensified financial challenges.
- Market Reaction: Given the poor financial performance, Ultralife's stock price may face pressure, prompting investors to monitor the company's future strategic adjustments and cost control measures to enhance profitability.
See More
Ultralife Corporation to Report Q1 2026 Results
- Earnings Release Schedule: Ultralife Corporation is set to report its first quarter financial results for the period ending March 31, 2026, before the market opens on May 8, 2026, which is expected to provide investors with the latest performance data to assess the company's financial health.
- Investor Conference Call: The management will host an investor conference call and simultaneous webcast at 8:30 AM ET on the same day, aiming to communicate directly with investors, enhance transparency, and boost investor confidence.
- Pre-registration Requirement: To ensure a smooth connection to the conference call, participants are required to pre-register using the provided link, a measure designed to streamline the participation process and reduce interaction with operators, thereby improving meeting efficiency.
- Live Webcast and Replay: The call will be available via live webcast in the Events & Presentations section of the company's website, and investors who cannot listen live will have access to a replay shortly after the call, ensuring widespread dissemination and access to information.
See More
Ultralife Reports Q4 Revenue Growth Amid Losses
- Revenue Growth: Ultralife reported Q4 revenue of $48.5 million, a 10.6% year-over-year increase, with full-year revenue reaching $191.2 million, reflecting a 16.2% growth, indicating strong performance in the battery and energy products segment.
- Loss Situation: Despite revenue growth, Ultralife reported an operating loss of $10.6 million for Q4 and a full-year loss of $5.9 million, resulting in a loss of $0.35 per share, highlighting the negative impact of non-cash impairments on financials.
- Backlog Growth: The company’s backlog reached $110.2 million at the end of Q4, a 22.1% increase from the previous quarter, indicating strong future demand, particularly in the medical and industrial sectors.
- Communication System Challenges: The communication systems segment experienced a 35.2% revenue decline, primarily due to delayed orders from the US government shutdown, revealing profitability pressures faced by this segment in the short term.
See More
Ultralife Reports Q4 Results with Revenue Growth and Improved EBITDA
- Financial Performance: Ultralife's Q4 report reveals a GAAP EPS of -$0.45, indicating a loss; however, revenue reached $48.48 million, reflecting a 10.6% year-over-year increase, showcasing the company's sales growth potential in the market.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose to $5.7 million, up from $3.9 million in the same quarter last year, indicating enhanced operational efficiency and effective cost management.
- Increased Backlog: Ultralife's backlog stood at $110.2 million at the end of 2025, compared to $90.3 million at the end of Q3, demonstrating strong future revenue support and sustained market demand.
- Optimistic Market Outlook: Despite reporting a loss, Ultralife's revenue and EBITDA growth, along with the increase in backlog, suggest a solid development potential for the company in future market competition.
See More
